Inventor · disambiguated record
Harvey Cantor
Also filed as: CANTOR HARVEY · CANTOR HARVEY I
20 granted patents·7 pending applications·217 citations·filing 1982–2023
94Inventor score
Top patents by PatentIndex Score
27 records- 0194US11597934B2Methods and compositions for reducing immunosuppression by tumor cellsDANA FARBER CANCER INST INC·Filed 2020·Granted Mar 7, 2023·3 cites·20 claims
- 0291US10876120B2Methods and compositions for reducing immunosupression by tumor cellsDANA FARBER CANCER INST INC·Filed 2018·Granted Dec 29, 2020·5 cites·9 claims
- 0391US5049659AProteins which induce immunological effector cell activation and chemattractionDANA FARBER CANCER INST INC·Filed 1988·Granted Sep 17, 1991·81 cites·25 claims
- 0488US9944931B2Methods and compositions for reducing immunosupression by tumor cellsDANA FARBER CANCER INST INC·Filed 2014·Granted Apr 17, 2018·11 cites·11 claims
- 0586US10548957B2Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritisDANA FARBER CANCER INST INC·Filed 2013·Granted Feb 4, 2020·6 cites·5 claims
- 0679US10596195B2Discovery of regulatory T cells programmed to suppress an immune responseDANA FARBER CANCER INST INC·Filed 2017·Granted Mar 24, 2020·3 cites·8 claims
- 0779US2023383298A1Methods and Compositions for Reducing Immunosupression by Tumor CellsDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 0877US12202904B2IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cellsDANA FARBER CANCER INST INC·Filed 2023·Granted Jan 21, 2025·0 cites·4 claims
- 0977US4559310AAssay methods and systems utilizing mast cell clonesDANA FARBER CANCER INST INC·Filed 1983·Granted Dec 17, 1985·33 cites·19 claims
- 1074US11590213B2Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritisDANA FARBER CANCER INST INC·Filed 2019·Granted Feb 28, 2023·0 cites·15 claims
- 1174US2023302106A1Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritisDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1269US5238839ANucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cellsDANA FARBER CANCER INST INC·Filed 1991·Granted Aug 24, 1993·26 cites·25 claims
- 1364US2025381277A1Compositions and methods for treatment of neurological disordersDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1463US11371989B2Intracellular osteopontin regulates the lineage commitment of lymphoid subsetsDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 28, 2022·0 cites·8 claims
- 1562US11591403B2IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cellsDANA FARBER CANCER INST INC·Filed 2018·Granted Feb 28, 2023·0 cites·15 claims
- 1660US7160986B2BCL-xγ, a novel BCL-x isoform, and uses related theretoDANA FARBER CANCER INST INC·Filed 2002·Granted Jan 9, 2007·0 cites·5 claims
- 1760US4722998AMethod of producing lymphocyte growth factorsDANA FARBER CANCER INST INC·Filed 1986·Granted Feb 2, 1988·13 cites·10 claims
- 1857US2024415919A1Compositions and methods for treatment of autoimmune disorders and cancerDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1955US4613459ALymphocyte growth factorDANA FARBER CANCER INST INC·Filed 1982·Granted Sep 23, 1986·14 cites·13 claims
- 2053US4952499AGenes and their encoded proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retrovirusesDANA FARBER CANCER INST INC·Filed 1988·Granted Aug 28, 1990·11 cites·23 claims
- 2150US2017269076A1Intracellular osteopontin regulates the lineage commitment of lymphoid subsetsDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 2244US8197817B2Regulation of mink in thymocytes and T lymphocytesCANTOR HARVEY·Filed 2005·Granted Jun 12, 2012·0 cites·4 claims
- 2342US4720482APharmaceutical compositions containing one or more lymphocyte growth factorsDANA FARBER CANCER INST INC·Filed 1986·Granted Jan 19, 1988·8 cites·4 claims
- 2442US2019192565A1Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapyDANA FARBER CANCER INST INC·Filed 2016·Application pending·0 cites
- 2537US2013302276A1Discovery of regulatory t cells programmed to suppress an immune responseCANTOR HARVEY·Filed 2011·Application pending·0 cites
- 2635US6472170B1BCL-Xy, a novel BCL-X isoform, and uses related theretoDANA FARBER CANCER INST INC·Filed 1997·Granted Oct 29, 2002·2 cites·18 claims
- 2730US5149785AProteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retrovirusesDANA FARBER CANCER INST INC·Filed 1990·Granted Sep 22, 1992·1 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Harvey Cantor files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →